reports
Nextensa sells its participation in Belgian REIT Retail Estates
Nextensa sells its participation in Belgian REIT Retail Estates PRESS RELEASE REGULATED INFORMATIONINSIDE INFORMATIONBrussels, 28 August 2025, 18:30 CEST Brussels, 28 August 2025 - Nextensa announces today that it has sold its entire 8.99% stake in the Belgian REIT Retail Estates. The deal was completed at a price of €66.30 per share, resulting in total proceeds of €89.6 million. This represents a substantial capital gain compared to the valuation applied in Nextensa’s half-year results published on 13 August 2025 (€61.50 per share).The transaction generates a strong inflow of cash, lo...
Nextensa vend sa participation dans SIR belge Retail Estates
Nextensa vend sa participation dans SIR belge Retail Estates COMMUNIQUÉ DE PRESSE INFORMATION RÉGLEMENTÉEINFORMATION PRIVILÉGIÉEBruxelles, 28 août 2025, 18h30 Bruxelles, 28 août 2025 - Nextensa annonce aujourd'hui qu'elle a vendu l'intégralité de sa participation de 8,99% dans la SIR belge Retail Estates. La transaction a été réalisée à un prix de 66,30 € par action, pour un montant total de 89,6 millions d'euros. Cela correspond à une plus-value significative par rapport à la valorisation reprise dans les résultats semestriels de Nextensa du 13 ao...
Nextensa verkoopt participatie in Belgische GVV Retail Estates
Nextensa verkoopt participatie in Belgische GVV Retail Estates PERSBERICHT GEREGLEMENTEERDE INFORMATIEVOORWETENSCHAPBrussel, 28 augustus 2025, 18u30 Brussel, 28 augustus 2025 - Nextensa maakt vandaag bekend dat zij haar volledige participatie van 8,99% in de Belgische GVV Retail Estates heeft verkocht. De deal werd afgerond tegen een prijs van €66,30 per aandeel, goed voor een opbrengst van €89,6 miljoen. Dit vertegenwoordigt een aanzienlijke meerwaarde ten opzichte van de waardering die werd opgenomen in Nextensa’s halfjaarresultaten van 13 augustus 2025 (€61,50 per aandeel). De tran...
argenx to Present at Upcoming Investor Conferences
argenx to Present at Upcoming Investor Conferences August 28, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following investor conferences in September: 2025 Wells Fargo Healthcare Conference. Fireside chat on Thursday, September 4, 2025 at 8:00 a.m. ET in Boston, MA.Morgan Stanley 23rd Annual Global Healthcare Conference. Fireside chat on Monday, September 8, 2025 at 7:00 a.m. ET i...
- Dirk Verbiesen
- Quirijn Mulder
Fugro/Trough passed/BUY
We expected a halving of EBIT YoY, but it was more as 2Q25 ended at -80% largely due to US offshore wind, lower vessel availability and postponements of large contracts. Fugro expects 2H revenues to increase by 20% HoH as elements of the downturn should not return in 3Q/4Q such as vessels and project postponements. Consequently, with delayed contracts now being executed, we feel comfortable with the company's view on 2H25. Including 2Q25, we have lowered our FY25-27F estimates, for the third tim...
- ING Helpdesk
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
- Wim Lewi
Retail Estates Leen Bakker gets court protection in Belgium
Leen Bakker België NV is currently under judicial protection as of 14th August 2025 and seeks buyers for its 44 stores to avoid closure. We believe this will have a limited impact on Retail Estates that leases 11 retail properties to Leen Bakker in BE. This makes up 1.39% of the rental income, while there are no arrears. The chain is owned by private equity company Gilde that bought it from Blokker Holding in 2017 and merged it with Kwantum. Both are related to home furnishing and rely on out-of...
The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, s...
The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Regulated information August 27, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Group performance: Strong HealthCare IT performance and stable Digital Print & Chemicals performance not sufficiently offsetting the continued fast decline in medical filmAdjusted EBITDA decreased...
De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestati...
De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Gereglementeerde informatie 27 augustus 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Groepsprestatie: Sterke prestatie van HealthCare IT en stabiele prestatie van Digital Print & Chemicals volstaan niet om de ...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Michiel Declercq
- Wim Lewi
- Jacob Mekhael
argenx Vyvgart meets primary endpoint in snMG paving path for label ex...
argenx announced positive topline data from the pivotal ADAPT SERON study of Vyvgart in AchR-Ab seronegative gMG (snMG), showing a statistically significant improvement vs. placebo (p-value=0.0068) on the primary endpoint of MG-ADL. The positive topline results do not come as a surprise, and confirm previously reported pooled analysis showing improvements in the MG-ADL score in this gMG sub-population. The company plans to file for label expansion with the FDA, and estimates the commercial oppor...
argenx Announces Positive Topline Results from ADAPT SERON Study of VY...
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG Study met primary endpoint (p-value=0.0068) First global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – MuSK+, LRP4+, triple seronegative Supplemental Biologics License Application (sBLA) to be submitted to U.S. Food and Drug Administration (FDA) by end of 2025 August 25, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving t...
Argen X SE: 1 director
A director at Argen X SE sold 426 shares at 547.910EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025 August 19, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET. The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thomas Couvreur
- Wim Lewi
- Kristof Samoy
Fugro A Convincing Path to 2H Recovery & Deep Discount Opportunity
We revisited our case following the recent profit warning but recognise 2Q25 already showed a remarkable q/q improvement in profitability to be continued in 2H25. The cheap valuation, strong balance sheet (1.2x EBITDA leverage and no debt maturities prior to 2029) next to the optionality in the future capex spend make that Fugro can weather further storms should they occur. At the speculative front with the mid and long term fundamentals intact potential renewed ownership interest by cash rich d...
Nextensa NV/SA: Half Year results 2025
Nextensa NV/SA: Half Year results 2025 PRESS RELEASE REGULATED INFORMATIONBrussels, 13 August 2025, 5:40 PM Solid half-year results confirm Nextensa’s strategic course In the first half of 2025, Nextensa achieved a clear increase in profitability despite a challenging economic context. Net profit increased significantly, driven by a higher contribution from development activities, lower financing costs, and a further strengthening of the balance sheet. Underlying rental income recorded positive like-for-like growth, mainly thanks to improved occupancy at Moonar and Tour & Taxis...
Nextensa SA: RESULTATS SEMESTRIELS 2025
Nextensa SA: RESULTATS SEMESTRIELS 2025 COMMUNIQUÉ DE PRESSE INFORMATION REGLEMENTÉE Bruxelles, 13 août 2025, 17h40 Des résultats semestriels solides confirment la stratégie de Nextensa Au premier semestre 2025, Nextensa a enregistré une nette augmentation de sa rentabilité malgré un contexte économique difficile. Le résultat net a fortement progressé, porté par une contribution plus élevée des activités de développement, des coûts de financement réduits et un renforcement supplémentaire du bilan. Les revenus locatifs sous-jacents ont affiché une croissance positi...
Nextensa NV: HALFJAAR RESULTATEN 2025
Nextensa NV: HALFJAAR RESULTATEN 2025 PERSBERICHT GEREGLEMENTEERDE INFORMATIE Brussel, 13 augustus 2025, 17u40 Solide halfjaarresultaten bevestigen strategische koers van Nextensa In de eerste helft van 2025 realiseerde Nextensa een duidelijke toename van de winstgevendheid, ondanks een uitdagende economische context. Het nettoresultaat steeg aanzienlijk, gedreven door een hogere bijdrage van de ontwikkelingsactiviteiten, lagere financieringskosten en een verdere versterking van de balans. De onderliggende huurinkomsten kenden een positieve like-for-like groei, voorna...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.